suloctidil and Thrombosis

suloctidil has been researched along with Thrombosis* in 4 studies

Reviews

3 review(s) available for suloctidil and Thrombosis

Article	Year
Antiplatelet drugs in the management of patients with thrombotic disorders. Seminars in thrombosis and hemostasis, 1986, Volume: 12, Issue:2 Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets; Catheterization; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Glomerulonephritis; Humans; Sulfinpyrazone; Suloctidil; Thiophenes; Thrombophlebitis; Thrombosis; Ticlopidine; Vascular Diseases; Vascular Surgical Procedures	1986
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries. Agents and actions. Supplements, 1984, Volume: 15 Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; Humans; Intermittent Claudication; Leg; Platelet Aggregation; Platelet Factor 4; Suloctidil; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine	1984
Action of drugs on the aggregation and deformability of red cells: effect of ABO blood groups. Annals of the New York Academy of Sciences, 1983, Volume: 416 Topics: ABO Blood-Group System; Alprenolol; Blood Coagulation; Blood Viscosity; Cell Adhesion; Erythrocyte Aggregation; Erythrocytes; Heart Diseases; Hemodynamics; Humans; Hyperlipidemias; Mathematics; Pentoxifylline; Rheology; Smoking; Suloctidil; Thrombosis	1983

Trials

1 trial(s) available for suloctidil and Thrombosis

Article	Year
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries. Agents and actions. Supplements, 1984, Volume: 15 Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; Humans; Intermittent Claudication; Leg; Platelet Aggregation; Platelet Factor 4; Suloctidil; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine	1984

Article

Year

Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.

Agents and actions. Supplements, 1984, Volume: 15

Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; Humans; Intermittent Claudication; Leg; Platelet Aggregation; Platelet Factor 4; Suloctidil; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine

1984

Other Studies

1 other study(ies) available for suloctidil and Thrombosis

Article	Year
Studies of suloctidil in experimental thrombosis in baboons. Thrombosis and haemostasis, 1985, Jun-24, Volume: 53, Issue:3 Suloctidil has been evaluated in the baboon for its antithrombotic efficacy using models of both acute and chronic arterial thrombogenesis. Acute thrombus formation was initiated by Dacron vascular grafts inserted as extension segments into chronic arteriovenous shunts. 111In-platelet deposition was measured by scintillation camera imaging for one hour. The results after oral administration of suloctidil (100 mg/kg/d in two divided doses) were not different from control studies. Moreover, concurrent heparin anticoagulation did not affect 111In-platelet deposition compared with control data. In contrast, ticlopidine (20 mg/kg/d) significantly decreased platelet deposition that was reduced further by the addition of heparin. Chronic arterial-thromboembolism was initiated by segments of polyurethane (Biomer) cannula introduced into chronic arteriovenous shunts. Thrombus formation by the polyurethane cannula was measured as 111In-platelet turnover (corrected for removal of senescent platelets). Cannula platelet consumption was unaffected by suloctidil (20 mg/kg/d given in two divided doses for two days preceding and throughout the period of platelet survival measurement). In contrast, dipyridamole (10 mg/kg/d) and sulfinpyrazone (100 mg/kg/d) completely interrupted cannula platelet consumption. We conclude that suloctidil probably has little or no effect on platelet-dependent thrombus formation. Topics: Acute Disease; Animals; Blood Platelets; Chronic Disease; Disease Models, Animal; Indium; Kinetics; Male; Papio; Platelet Count; Propanolamines; Radioisotopes; Suloctidil; Thromboembolism; Thrombosis	1985

Article

Year

Studies of suloctidil in experimental thrombosis in baboons.

Thrombosis and haemostasis, 1985, Jun-24, Volume: 53, Issue:3

Suloctidil has been evaluated in the baboon for its antithrombotic efficacy using models of both acute and chronic arterial thrombogenesis. Acute thrombus formation was initiated by Dacron vascular grafts inserted as extension segments into chronic arteriovenous shunts. 111In-platelet deposition was measured by scintillation camera imaging for one hour. The results after oral administration of suloctidil (100 mg/kg/d in two divided doses) were not different from control studies. Moreover, concurrent heparin anticoagulation did not affect 111In-platelet deposition compared with control data. In contrast, ticlopidine (20 mg/kg/d) significantly decreased platelet deposition that was reduced further by the addition of heparin. Chronic arterial-thromboembolism was initiated by segments of polyurethane (Biomer) cannula introduced into chronic arteriovenous shunts. Thrombus formation by the polyurethane cannula was measured as 111In-platelet turnover (corrected for removal of senescent platelets). Cannula platelet consumption was unaffected by suloctidil (20 mg/kg/d given in two divided doses for two days preceding and throughout the period of platelet survival measurement). In contrast, dipyridamole (10 mg/kg/d) and sulfinpyrazone (100 mg/kg/d) completely interrupted cannula platelet consumption. We conclude that suloctidil probably has little or no effect on platelet-dependent thrombus formation.

Topics: Acute Disease; Animals; Blood Platelets; Chronic Disease; Disease Models, Animal; Indium; Kinetics; Male; Papio; Platelet Count; Propanolamines; Radioisotopes; Suloctidil; Thromboembolism; Thrombosis

1985